CanariaBio, Inc.
CanariaBio is a biotechnology company with assets for research and development of immuno-anticancer treatments. We have pipelines for the development of various immunotherapeutic for ovarian cancer, pancreatic cancer, and breast cancer. Our lead product oregovomab, an ovarian cancer treatment, was able to improve PFS by 30months when given with chemotherapy in phase 2. We are currently running the phase 3 study in 16 different countries at 162 sites. For more information about us, please visit www.canariabio.com.